The inflammatory bowel disease (IBD) is incurable, chronic, recrudescent disorders in the
inflamed intestines. Current clinic treatments are challenged by systemic exposure-induced …

The incidence of inflammatory bowel disease (IBD) is rapidly rising throughout the world.
Although tremendous efforts have been made, limited therapeutics are available for IBD …

Although synthesized nanotherapeutics (NTs) are attractive for the oral treatment of colon
diseases, their clinical translations are constrained by the unsatisfactory therapeutic …

Although multitudinous nanoscale drug-delivery systems (DDSs) have been recommended
to improve anti-ulcerative colitis (UC) outcomes, to enhance the mucoadhesion of …

Orally targeted strategy of anti-inflammatory agents has attracted tremendous attention for
reducing highly health-care costs and enhancing the intervention efficiency of ulcerative …

Overcoming the reticuloendothelial system (RES) has long been a vital challenge to
nanoparticles as drug carriers. Modification of nanoparticles with polyethylene glycol helps …

Inflammation is intimately related to the pathogenesis of numerous acute and chronic
diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and …

The therapeutic outcomes of oral nanomedicines against colon cancer are heavily
compromised by their lack of specific penetration into the internal tumor, favorable anti …

Although magnolol (Mag), an anti-inflammatory natural compound, has been demonstrated
to play protective effects on ulcerative colitis (UC), its application as an alternative …

Ulcerative colitis (UC) with its rapidly increasing incidence has become an emerging
challenge for public health. Therapeutic agents are required to be specifically delivered to …